Xtl Biopharmaceuticals (XTLB) Debt Ratio (2010 - 2025)
Xtl Biopharmaceuticals (XTLB) posted quarterly Debt Ratio of 0.83 for Q4 2025, up 5050.6% year-on-year from 0.02 in Q4 2024, and up 5050.6% on a QoQ basis from 0.02 in Q4 2024.
Xtl Biopharmaceuticals (XTLB) Debt Ratio (2010 - 2025) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Debt Ratio for 5 consecutive years, with 0.83 the latest figure, recorded in Q4 2025.
- Quarterly Debt Ratio rose 5050.6% year-over-year to 0.83 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.83 (up 5050.6% YoY) and the FY2025 annual result came in at 0.83, up 5050.6% from the prior year.
- Debt Ratio grew to 0.83 in Q4 2025 per XTLB's latest filing, from 0.02 in the prior quarter.
- Over the last five years, Debt Ratio for XTLB reached as high as 0.83 in Q4 2025 and fell as low as 0.02 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | 1.41 |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn | 0.11 |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn | 0.05 |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - | - |
| 10 | Xtl Biopharmaceuticals | 2.58 Bn | 2.58 Bn | - | 0.83 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.83 |
| Dec 31, 2024 | 0.02 |
| Dec 31, 2017 | 0.40 |
| Dec 31, 2011 | 1,000.01 |
| Dec 31, 2010 | 1,000.00 |